Psoriatic arthritis patients who switch anti-TNFi drugs fare worse

04/26/2013 | Family Practice News

Patients with psoriatic arthritis who switched to a second anti-tumor necrosis factor inhibitor drug had lower drug-survival rates at three years compared with those who remained on their first medication, researchers in Norway found. Switchers also showed much poorer responses in factors such as Disease Activity Score-28 remission and American College of Rheumatology-50 response than non-switchers. The findings were published in the journal Annals of the Rheumatic Diseases.

View Full Article in:

Family Practice News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT